HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Metformin decreases high-fat diet-induced renal injury by regulating the expression of adipokines and the renal AMP-activated protein kinase/acetyl-CoA carboxylase pathway in mice.

Abstract
Metabolic syndrome is characterized by insulin resistance, dyslipidemia and hypertension. These metabolic changes contribute to the development of obesity-induced kidney injury. AMP-activated protein kinase (AMPK) is a ubiquitous enzyme that is involved in the cellular metabolic response to metabolic stress. Metformin, an AMPK activator, has been reported to exert a protective effect against non-alcoholic steatohepatitis. However, little is known about its role in the pathogenesis of obesity-induced renal injury. The aim of this study was to investigate the effects of metformin on high-fat diet (HFD)-induced kidney injury. Obesity was induced by HFD (60% of total calories from fat, 20% protein and 20% carbohydrates) in 6-week-old C57BL/6 mice. Mice were fed HFD plus 0.5% metformin. The effects of metformin on HFD-induced renal injury were evaluated by determining metabolic parameters, serum adipokine levels and renal AMPK/acetyl-CoA carboxylase (ACC) activities, as well as a histological examination. HFD induced metabolic derangement, systemic insulin resistance and glomerular mesangial matrix expansion. The administration of metformin reduced HFD-induced metabolic derangement and renal injury. The administration of metformin reduced the HFD-induced increase in adipokine expression and macrophage infiltration. Moreover, renal AMPK activity, which was decreased by HFD, was recovered following the administration of metformin; in addition, fatty acid oxidation was increased by the inhibition of ACC. These results indicate that metformin exerts beneficial effects on obesity-induced renal injury by regulating systemic inflammation, insulin resistance and the renal AMPK/ACC pathway. The clinical application of metformin to obese or early diabetic patients may be helpful in preventing obesity- or diabetes-related kidney disease.
AuthorsDal Kim, Jung Eun Lee, Yu Jin Jung, Ae Sin Lee, Sik Lee, Sung Kwang Park, Suhn Hee Kim, Byung-Hyun Park, Won Kim, Kyung Pyo Kang
JournalInternational journal of molecular medicine (Int J Mol Med) Vol. 32 Issue 6 Pg. 1293-302 (Dec 2013) ISSN: 1791-244X [Electronic] Greece
PMID24068196 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adipokines
  • Transforming Growth Factor beta1
  • Metformin
  • AMP-Activated Protein Kinases
  • Acetyl-CoA Carboxylase
Topics
  • AMP-Activated Protein Kinases (metabolism)
  • Acetyl-CoA Carboxylase (metabolism)
  • Adipokines (blood, metabolism)
  • Animals
  • Diet, High-Fat
  • Glucose Intolerance (blood, drug therapy, enzymology, pathology)
  • Inflammation (pathology)
  • Insulin Resistance
  • Kidney (drug effects, enzymology, pathology)
  • Kidney Tubules (drug effects, metabolism, pathology)
  • Male
  • Metformin (pharmacology)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Obese
  • Oxidation-Reduction (drug effects)
  • Podocytes (drug effects, metabolism, pathology)
  • Signal Transduction (drug effects)
  • Transforming Growth Factor beta1 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: